The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks soured by Wall Street sell-off and 'vaccine nationalism'

Thu, 28th Jan 2021 09:11

* Asian stock markets : https://tmsnrt.rs/2zpUAr4

* Easyjet highlights pain of airlines during lockdown

* Talk of distressed selling by hedge funds as shorts
squeezed

* Dollar gets safe-haven bid as euro backtracks

By Huw Jones

LONDON, Jan 28 (Reuters) - Shares wiped out their gains in
Europe for the year early on Thursday, soured by a sell-off on
Wall Street, no end in sight to pandemic lockdowns and a squeeze
in short positions.

The pan-European STOXX benchmark was down 1.8% at
395.77 points, its lowest since December. London, Paris
and Frankfurt all fell.

"The initial optimism of early this year is starting to
dissipate because of the prospects of tighter pandemic
restrictions for longer, and concerns over 'vaccine
nationalism'," said Michael Hewson, chief market analyst at CMC
Markets.

The European Union, locked in a public spat with vaccine
producer AstraZeneca, wants a shortfall in the company's
supplies to the bloc topped up from production in Britain.

Easyjet shares fell 2.3% after the airline warned it
would fly no more than 10% of 2019's capacity, highlighting the
plight of sectors hit by lengthy lockdowns.

The move by investors into "reflation" trades at the start
of the year on then-brighter growth prospects now looked
premature, analysts said.

"Amid concerns about the speed of vaccine distribution and
the COVID-19 impact on economic growth recovery, cyclical credit
looks most likely to underperform," UniCredit analysts said.

Wall Street on Wednesday suffered its biggest one-day
percentage drop in three months as the S&P500 index and Nasdaq
Composite fell 2.6%.

Some pointed a finger at U.S. retail investors who had
forced a massive squeeze on hedge funds that held short
positions in stocks such as GameStop.

"We could see much more choppiness and much more volatility.
We have a bit of a perfect storm heading into the month end,
which is weighing on equity markets, but I don't think at the
moment we are in a place where it's going to come crashing off,"
Hewson said.

On the data front, analysts said the focus will be on German
inflation figures and fourth-quarter U.S. economic growth.

Yields on the 10-year U.S. Treasury bond fell
below 1% for the first time in three weeks overnight in a
further sign of a shrinking demand for risk.

ASIA WEAKER

Asian shares slid on Thursday while the safe-haven dollar
rallied as Wall Street's sell-off and delays in coronavirus
vaccines provided an excuse to book profits on recent gains.

MSCI's broadest index of Asia-Pacific shares outside Japan
fell 2%, with valuations looking stretched after
the index rose more than 6% just this month.

Japan's Nikkei fell 1.5%, its sharpest drop since
October, and Chinese blue chips lost 2.7% as liquidity
tightened before the Lunar New Year holidays.

South Korea fell 1.7%, led by losses in Samsung
after it reported earnings.

Even the tech darlings were not immune. Facebook
dropped despite reporting earnings well above expectations.
Apple Inc also handily beat forecasts, but its shares
lost 3% after the bell.

Dealers noted the market had focused more on a downbeat
economic outlook from the Federal Reserve overnight than on its
pledge of continued policy support.

The safe-haven U.S. dollar gained, with its index up at
90.771 from a January low of 89.206.

The euro fell to $1.2093 amid reports the European
Central Bank felt markets were under-pricing the risk of more
rate cuts.

The bounce in the dollar kept gold prices soft around $1,837
an ounce.

Global demand concerns restrained oil prices despite a drop
in U.S. crude stocks. U.S. crude fell 34 cents to $52.51
a barrel. Brent crude futures dropped to $55.50.

(Additional reporting by Alwyn Scott; editing by Christian
Schmollinger, Ana Nicolaci da Costa, Larry King)

More News
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.